MA42061A - K-RAS MODULATORS - Google Patents
K-RAS MODULATORSInfo
- Publication number
- MA42061A MA42061A MA042061A MA42061A MA42061A MA 42061 A MA42061 A MA 42061A MA 042061 A MA042061 A MA 042061A MA 42061 A MA42061 A MA 42061A MA 42061 A MA42061 A MA 42061A
- Authority
- MA
- Morocco
- Prior art keywords
- ras modulators
- ras
- modulators
- Prior art date
Links
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562157915P | 2015-05-06 | 2015-05-06 | |
| US201562158356P | 2015-05-07 | 2015-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42061A true MA42061A (en) | 2021-03-31 |
Family
ID=57218009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042061A MA42061A (en) | 2015-05-06 | 2016-05-06 | K-RAS MODULATORS |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10857140B2 (en) |
| EP (1) | EP3291813A4 (en) |
| JP (1) | JP6771023B2 (en) |
| KR (1) | KR20180017013A (en) |
| CN (1) | CN107847495A (en) |
| AU (1) | AU2016258192B2 (en) |
| BR (1) | BR112017023821A2 (en) |
| CA (1) | CA2983927A1 (en) |
| CL (2) | CL2017002786A1 (en) |
| EA (1) | EA201792443A1 (en) |
| EC (1) | ECSP17073743A (en) |
| HK (2) | HK1251485A1 (en) |
| IL (1) | IL255417A (en) |
| MA (1) | MA42061A (en) |
| MX (1) | MX2017014163A (en) |
| PH (1) | PH12017501999A1 (en) |
| WO (1) | WO2016179558A1 (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104379563B (en) | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | Composition and method for treating cancer |
| CA2983927A1 (en) | 2015-05-06 | 2016-11-10 | The Regents Of The University Of California | K-ras modulators |
| AU2017266911B2 (en) | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
| SG11201909570PA (en) | 2017-04-20 | 2019-11-28 | Univ California | K-ras modulators |
| EP3710439B1 (en) | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| TW202012396A (en) * | 2018-04-18 | 2020-04-01 | 美商德洛斯股份有限公司 | K-ras modulators with a vinyl sulfonamide moiety |
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| US12336995B2 (en) | 2018-09-10 | 2025-06-24 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020055760A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| HRP20250059T1 (en) | 2018-09-10 | 2025-03-28 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022509724A (en) | 2018-12-05 | 2022-01-24 | ミラティ セラピューティクス， インコーポレイテッド | Combination therapy |
| JP7592601B2 (en) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | KRAS G12C inhibitors |
| EP3946629A4 (en) * | 2019-03-26 | 2023-04-05 | University Of Massachusetts | THERAPEUTIC TARGETS FOR ONCOGENIC AND S-DEPENDENT CANCER |
| JP7622043B2 (en) | 2019-08-29 | 2025-01-27 | ミラティ セラピューティクス， インコーポレイテッド | KRAS G12D inhibitors |
| AU2020356455A1 (en) | 2019-09-24 | 2022-04-14 | Mirati Therapeutics, Inc. | Combination therapies |
| CN110981943B (en) * | 2019-12-02 | 2021-08-03 | 清华大学 | Polypeptide, application thereof in preparation of medicine and medicine |
| CN115135315B (en) | 2019-12-20 | 2024-11-26 | 米拉蒂治疗股份有限公司 | SOS1 inhibitors |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| JP2023523323A (en) * | 2020-04-27 | 2023-06-02 | ベラステム・インコーポレーテッド | Methods of treating abnormal cell growth |
| TW202210633A (en) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | A dbait molecule in combination with kras inhibitor for the treatment of cancer |
| EP4168002A1 (en) | 2020-06-18 | 2023-04-26 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| JP2023540809A (en) | 2020-09-11 | 2023-09-26 | ミラティ セラピューティクス， インコーポレイテッド | Crystal form of KRAS G12C inhibitor |
| KR20230142465A (en) | 2020-12-15 | 2023-10-11 | 미라티 테라퓨틱스, 인크. | Azaquinazoline pan-KRas inhibitor |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| EP4330228A4 (en) * | 2021-04-26 | 2025-03-26 | The Regents of the University of California | G-alpha-s inhibitors and uses thereof |
| EP4389751A1 (en) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| KR20250136379A (en) * | 2023-01-18 | 2025-09-16 | 몰레큘라 악시옴, 엘엘씨 | Composition for regulating KRAS expression and use thereof |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| TW202502779A (en) | 2023-06-30 | 2025-01-16 | 美商金橘生物科技公司 | Substituted heteroaromatic amines and uses thereof |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025230971A1 (en) | 2024-04-30 | 2025-11-06 | Kumquat Biosciences Inc. | Macrocyclic heterocycles as anticancer agents |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3131527A1 (en) | 1981-08-08 | 1983-02-24 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 1-PHENYL-2-AMINOCARBONYLINDOL COMPOUNDS AND METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
| JPS61227567A (en) * | 1985-04-01 | 1986-10-09 | Eisai Co Ltd | 1,4-dihydropyridine derivative |
| DK626889A (en) | 1988-12-16 | 1990-06-17 | Roussel Uclaf | INDANDER DERIVATIVES, THEIR PREPARATION AND MEDICINES WITH CONTENTS |
| IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same |
| WO1996006078A1 (en) | 1994-08-24 | 1996-02-29 | Pfizer Pharmaceuticals Inc. | N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists |
| US5475109A (en) * | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| US5631251A (en) | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | 5-cyclopropyl-1,4 benzodiazepine-2-ones |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| JP2003501414A (en) | 1999-06-04 | 2003-01-14 | アストラゼネカ・アクチエボラーグ | Metalloproteinase inhibitors |
| HUP0203542A3 (en) | 1999-08-12 | 2003-07-28 | Upjohn Co | 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same |
| US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| WO2003004474A1 (en) | 2001-07-06 | 2003-01-16 | Syngenta Participations Ag | Pesticidally active aminoacetonitriles |
| MXPA05003632A (en) * | 2002-10-11 | 2005-06-03 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors. |
| KR101146806B1 (en) | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | Phthalazinone derivatives |
| US20050119266A1 (en) | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
| GB0326029D0 (en) * | 2003-11-07 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| EP1683797A1 (en) | 2003-11-13 | 2006-07-26 | Ono Pharmaceutical Co., Ltd. | Heterocyclic spiro compound |
| AU2004299461A1 (en) | 2003-12-15 | 2005-06-30 | Almirall Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| ATE443701T1 (en) | 2004-01-16 | 2009-10-15 | Wyeth Corp | HETEROCYCLIC AZOLE-CONTAINING SULFONAMIDINE INHIBITORS OF BETA-AMYLOID PRODUCTION |
| ES2399447T3 (en) * | 2006-02-17 | 2013-04-01 | F. Hoffmann-La Roche Ag | Benzoyl-piperidine derivatives as 5HT2 / D3 modulators |
| CA2645652A1 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| US20100267779A1 (en) | 2007-07-23 | 2010-10-21 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
| SA08290475B1 (en) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2S,3R)-N-(2-((3-pyrdinyl)methyl)-1-aza bicyclo[2,2,2]oct-3-yl)benzofuran-2-carboxamide, its new salt forms and methods of use |
| DK2379537T5 (en) | 2008-12-19 | 2017-09-25 | Elanco Tiergesundheit Ag | Isoxazoline derivatives and their use as pesticides |
| CN102480957A (en) | 2009-05-27 | 2012-05-30 | Ptc医疗公司 | Methods of treating cancer and non-neoplastic conditions |
| US8324239B2 (en) | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
| CN104379563B (en) | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | Composition and method for treating cancer |
| EP2698367A1 (en) | 2012-08-14 | 2014-02-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benzimidazoles for the treatment of cancer |
| WO2014093230A2 (en) | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| MX364438B (en) * | 2013-03-15 | 2019-04-26 | Araxes Pharma Llc | Covalent inhibitors of kras g12c. |
| UY35464A (en) * | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | KRAS G12C COVALENT INHIBITORS. |
| US10196369B2 (en) * | 2013-09-26 | 2019-02-05 | Sanford Burnham Prebys Medical Discovery Institute | Spirocyclic EBI2 modulators |
| JP2018511614A (en) * | 2015-04-03 | 2018-04-26 | ナントバイオ，インコーポレイテッド | Compositions and methods targeting mutant K-RAS |
| CA2983927A1 (en) | 2015-05-06 | 2016-11-10 | The Regents Of The University Of California | K-ras modulators |
| JP7041070B2 (en) | 2016-04-15 | 2022-03-23 | エピザイム，インコーポレイティド | Amine-substituted aryl or heteroaryl compounds as EHMT1 and EHMT2 inhibitors |
| SG11201909570PA (en) | 2017-04-20 | 2019-11-28 | Univ California | K-ras modulators |
-
2016
- 2016-05-06 CA CA2983927A patent/CA2983927A1/en not_active Abandoned
- 2016-05-06 JP JP2018510695A patent/JP6771023B2/en not_active Expired - Fee Related
- 2016-05-06 EP EP16790206.3A patent/EP3291813A4/en not_active Withdrawn
- 2016-05-06 MA MA042061A patent/MA42061A/en unknown
- 2016-05-06 MX MX2017014163A patent/MX2017014163A/en unknown
- 2016-05-06 US US15/571,475 patent/US10857140B2/en not_active Expired - Fee Related
- 2016-05-06 BR BR112017023821A patent/BR112017023821A2/en not_active Application Discontinuation
- 2016-05-06 HK HK18111150.3A patent/HK1251485A1/en unknown
- 2016-05-06 EA EA201792443A patent/EA201792443A1/en unknown
- 2016-05-06 CN CN201680037365.9A patent/CN107847495A/en active Pending
- 2016-05-06 HK HK18111290.4A patent/HK1251972A1/en unknown
- 2016-05-06 AU AU2016258192A patent/AU2016258192B2/en not_active Ceased
- 2016-05-06 WO PCT/US2016/031344 patent/WO2016179558A1/en not_active Ceased
- 2016-05-06 KR KR1020177035079A patent/KR20180017013A/en not_active Withdrawn
-
2017
- 2017-11-02 PH PH12017501999A patent/PH12017501999A1/en unknown
- 2017-11-03 CL CL2017002786A patent/CL2017002786A1/en unknown
- 2017-11-03 IL IL255417A patent/IL255417A/en unknown
- 2017-11-06 EC ECIEPI201773743A patent/ECSP17073743A/en unknown
-
2018
- 2018-11-21 CL CL2018003316A patent/CL2018003316A1/en unknown
-
2020
- 2020-10-28 US US17/082,125 patent/US11541044B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2018003316A1 (en) | 2019-03-15 |
| KR20180017013A (en) | 2018-02-20 |
| AU2016258192B2 (en) | 2021-07-29 |
| PH12017501999A1 (en) | 2018-04-02 |
| ECSP17073743A (en) | 2018-03-31 |
| BR112017023821A2 (en) | 2018-07-31 |
| WO2016179558A1 (en) | 2016-11-10 |
| HK1251972A1 (en) | 2019-05-10 |
| EA201792443A1 (en) | 2018-10-31 |
| JP2018519357A (en) | 2018-07-19 |
| US20210196695A1 (en) | 2021-07-01 |
| MX2017014163A (en) | 2018-08-15 |
| US20180289683A1 (en) | 2018-10-11 |
| EP3291813A1 (en) | 2018-03-14 |
| IL255417A (en) | 2018-01-31 |
| CL2017002786A1 (en) | 2018-06-22 |
| CN107847495A (en) | 2018-03-27 |
| WO2016179558A8 (en) | 2017-11-16 |
| CA2983927A1 (en) | 2016-11-10 |
| AU2016258192A1 (en) | 2017-11-16 |
| HK1251485A1 (en) | 2019-02-01 |
| US11541044B2 (en) | 2023-01-03 |
| US10857140B2 (en) | 2020-12-08 |
| JP6771023B2 (en) | 2020-10-21 |
| EP3291813A4 (en) | 2019-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50014A (en) | K-RAS MODULATORS | |
| MA42061A (en) | K-RAS MODULATORS | |
| MA53943A (en) | ROR-GAMMA MODULATORS | |
| MA55328A (en) | ROR-GAMMA MODULATORS | |
| DK3283625T3 (en) | NUCLEASE-MEDIED GENOMEDITING | |
| EP3348489A4 (en) | CAP | |
| DK3297438T3 (en) | CCR2 MODULATORS | |
| DK3331528T3 (en) | MUSCARINAGONISTS | |
| DK3277719T3 (en) | POLYPEPTIDER | |
| DK3305788T3 (en) | JANUS-KINASE-HIMMER | |
| DK3331529T3 (en) | MUSCARINAGONISTS | |
| DK3310450T3 (en) | OIL-WATER-SEPARATOR | |
| PL3303293T3 (en) | Ror-gamma modulators | |
| PL3303291T3 (en) | Ror-gamma modulators | |
| PL3303290T3 (en) | Ror-gamma modulators | |
| DK3270930T3 (en) | PRE-CLAMPSY | |
| PL3319942T3 (en) | Ror-gamma modulators | |
| DK3292136T3 (en) | PENICILLIN-G-ACYLASER | |
| EP3532062A4 (en) | ROR-GAMMA MODULATORS | |
| DE112015006486A5 (en) | Inkubationsrinne | |
| DK3274482T3 (en) | STENBORSKNOP | |
| DE102015206660A8 (en) | Beamsaw | |
| DK3318308T3 (en) | BATHMIN TONKETS | |
| DE112015005898A5 (en) | Gurtschlossbringer | |
| DE112016005599A5 (en) | grillers |